The global Parkinson's Disease Therapeutics market size was valued at US$ 2717 million in 2024 and is forecast to a readjusted size of USD 4030 million by 2031 with a CAGR of 5.9% during review period.
Parkinson"s disease (PD), or simply Parkinson"s, is a chronic degenerative disorder of the central nervous system that affects both the motor system and non-motor systems. The symptoms usually emerge slowly, and as the disease worsens, non-motor symptoms become more common. Early symptoms are tremor, rigidity, slowness of movement, and difficulty with walking. Problems may also arise with cognition, behaviour, sleep, and sensory systems. Parkinson"s disease dementia becomes common in advanced stages of the disease.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Parkinson's Disease Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Parkinson's Disease Therapeutics market size and forecasts, in consumption value ($ Million), 2020-2031
Global Parkinson's Disease Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Parkinson's Disease Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Parkinson's Disease Therapeutics market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Parkinson's Disease Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Parkinson's Disease Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Roche, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Parkinson's Disease Therapeutics market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Other
麻豆原创 segment by Application
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
麻豆原创 segment by players, this report covers
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Roche
H.Lundbeck
Bausch Health
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Desitin Arzneimittel
Endo Pharmaceuticals
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Parkinson's Disease Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Parkinson's Disease Therapeutics, with revenue, gross margin, and global market share of Parkinson's Disease Therapeutics from 2020 to 2025.
Chapter 3, the Parkinson's Disease Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Parkinson's Disease Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Parkinson's Disease Therapeutics.
Chapter 13, to describe Parkinson's Disease Therapeutics research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Parkinson's Disease Therapeutics by Type
1.3.1 Overview: Global Parkinson's Disease Therapeutics 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Parkinson's Disease Therapeutics Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Sinemet-CR
1.3.4 Trastal
1.3.5 Madopar
1.3.6 COMT Inhibitor
1.3.7 Other
1.4 Global Parkinson's Disease Therapeutics 麻豆原创 by Application
1.4.1 Overview: Global Parkinson's Disease Therapeutics 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Under 40 Years Old
1.4.3 40-65 Years Old
1.4.4 Above 65 Years Old
1.5 Global Parkinson's Disease Therapeutics 麻豆原创 Size & Forecast
1.6 Global Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast by Region
1.6.1 Global Parkinson's Disease Therapeutics 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Parkinson's Disease Therapeutics 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Parkinson's Disease Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Parkinson's Disease Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Parkinson's Disease Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Parkinson's Disease Therapeutics 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Parkinson's Disease Therapeutics 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Merck
2.1.1 Merck Details
2.1.2 Merck Major Business
2.1.3 Merck Parkinson's Disease Therapeutics Product and Solutions
2.1.4 Merck Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Merck Recent Developments and Future Plans
2.2 Akorn
2.2.1 Akorn Details
2.2.2 Akorn Major Business
2.2.3 Akorn Parkinson's Disease Therapeutics Product and Solutions
2.2.4 Akorn Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Akorn Recent Developments and Future Plans
2.3 GSK
2.3.1 GSK Details
2.3.2 GSK Major Business
2.3.3 GSK Parkinson's Disease Therapeutics Product and Solutions
2.3.4 GSK Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 GSK Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Parkinson's Disease Therapeutics Product and Solutions
2.4.4 Novartis Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Novartis Recent Developments and Future Plans
2.5 Boehringer Ingelheim
2.5.1 Boehringer Ingelheim Details
2.5.2 Boehringer Ingelheim Major Business
2.5.3 Boehringer Ingelheim Parkinson's Disease Therapeutics Product and Solutions
2.5.4 Boehringer Ingelheim Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Boehringer Ingelheim Recent Developments and Future Plans
2.6 Teva Pharmaceutical
2.6.1 Teva Pharmaceutical Details
2.6.2 Teva Pharmaceutical Major Business
2.6.3 Teva Pharmaceutical Parkinson's Disease Therapeutics Product and Solutions
2.6.4 Teva Pharmaceutical Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Teva Pharmaceutical Recent Developments and Future Plans
2.7 Abbvie
2.7.1 Abbvie Details
2.7.2 Abbvie Major Business
2.7.3 Abbvie Parkinson's Disease Therapeutics Product and Solutions
2.7.4 Abbvie Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Abbvie Recent Developments and Future Plans
2.8 Kyowa Hakko Kirin Pharma
2.8.1 Kyowa Hakko Kirin Pharma Details
2.8.2 Kyowa Hakko Kirin Pharma Major Business
2.8.3 Kyowa Hakko Kirin Pharma Parkinson's Disease Therapeutics Product and Solutions
2.8.4 Kyowa Hakko Kirin Pharma Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Kyowa Hakko Kirin Pharma Recent Developments and Future Plans
2.9 Astellas Pharma
2.9.1 Astellas Pharma Details
2.9.2 Astellas Pharma Major Business
2.9.3 Astellas Pharma Parkinson's Disease Therapeutics Product and Solutions
2.9.4 Astellas Pharma Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Astellas Pharma Recent Developments and Future Plans
2.10 Roche
2.10.1 Roche Details
2.10.2 Roche Major Business
2.10.3 Roche Parkinson's Disease Therapeutics Product and Solutions
2.10.4 Roche Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Roche Recent Developments and Future Plans
2.11 H.Lundbeck
2.11.1 H.Lundbeck Details
2.11.2 H.Lundbeck Major Business
2.11.3 H.Lundbeck Parkinson's Disease Therapeutics Product and Solutions
2.11.4 H.Lundbeck Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 H.Lundbeck Recent Developments and Future Plans
2.12 Bausch Health
2.12.1 Bausch Health Details
2.12.2 Bausch Health Major Business
2.12.3 Bausch Health Parkinson's Disease Therapeutics Product and Solutions
2.12.4 Bausch Health Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Bausch Health Recent Developments and Future Plans
2.13 Apokyn
2.13.1 Apokyn Details
2.13.2 Apokyn Major Business
2.13.3 Apokyn Parkinson's Disease Therapeutics Product and Solutions
2.13.4 Apokyn Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Apokyn Recent Developments and Future Plans
2.14 Orion
2.14.1 Orion Details
2.14.2 Orion Major Business
2.14.3 Orion Parkinson's Disease Therapeutics Product and Solutions
2.14.4 Orion Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Orion Recent Developments and Future Plans
2.15 Stada Arzneimittel
2.15.1 Stada Arzneimittel Details
2.15.2 Stada Arzneimittel Major Business
2.15.3 Stada Arzneimittel Parkinson's Disease Therapeutics Product and Solutions
2.15.4 Stada Arzneimittel Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Stada Arzneimittel Recent Developments and Future Plans
2.16 US WorldMeds
2.16.1 US WorldMeds Details
2.16.2 US WorldMeds Major Business
2.16.3 US WorldMeds Parkinson's Disease Therapeutics Product and Solutions
2.16.4 US WorldMeds Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 US WorldMeds Recent Developments and Future Plans
2.17 Desitin Arzneimittel
2.17.1 Desitin Arzneimittel Details
2.17.2 Desitin Arzneimittel Major Business
2.17.3 Desitin Arzneimittel Parkinson's Disease Therapeutics Product and Solutions
2.17.4 Desitin Arzneimittel Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Desitin Arzneimittel Recent Developments and Future Plans
2.18 Endo Pharmaceuticals
2.18.1 Endo Pharmaceuticals Details
2.18.2 Endo Pharmaceuticals Major Business
2.18.3 Endo Pharmaceuticals Parkinson's Disease Therapeutics Product and Solutions
2.18.4 Endo Pharmaceuticals Parkinson's Disease Therapeutics Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Endo Pharmaceuticals Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Parkinson's Disease Therapeutics Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Parkinson's Disease Therapeutics by Company Revenue
3.2.2 Top 3 Parkinson's Disease Therapeutics Players 麻豆原创 Share in 2024
3.2.3 Top 6 Parkinson's Disease Therapeutics Players 麻豆原创 Share in 2024
3.3 Parkinson's Disease Therapeutics 麻豆原创: Overall Company Footprint Analysis
3.3.1 Parkinson's Disease Therapeutics 麻豆原创: Region Footprint
3.3.2 Parkinson's Disease Therapeutics 麻豆原创: Company Product Type Footprint
3.3.3 Parkinson's Disease Therapeutics 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Parkinson's Disease Therapeutics Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Parkinson's Disease Therapeutics 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Parkinson's Disease Therapeutics Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Parkinson's Disease Therapeutics 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Parkinson's Disease Therapeutics Consumption Value by Type (2020-2031)
6.2 North America Parkinson's Disease Therapeutics 麻豆原创 Size by Application (2020-2031)
6.3 North America Parkinson's Disease Therapeutics 麻豆原创 Size by Country
6.3.1 North America Parkinson's Disease Therapeutics Consumption Value by Country (2020-2031)
6.3.2 United States Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Parkinson's Disease Therapeutics Consumption Value by Type (2020-2031)
7.2 Europe Parkinson's Disease Therapeutics Consumption Value by Application (2020-2031)
7.3 Europe Parkinson's Disease Therapeutics 麻豆原创 Size by Country
7.3.1 Europe Parkinson's Disease Therapeutics Consumption Value by Country (2020-2031)
7.3.2 Germany Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Parkinson's Disease Therapeutics Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Parkinson's Disease Therapeutics Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Parkinson's Disease Therapeutics 麻豆原创 Size by Region
8.3.1 Asia-Pacific Parkinson's Disease Therapeutics Consumption Value by Region (2020-2031)
8.3.2 China Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Parkinson's Disease Therapeutics Consumption Value by Type (2020-2031)
9.2 South America Parkinson's Disease Therapeutics Consumption Value by Application (2020-2031)
9.3 South America Parkinson's Disease Therapeutics 麻豆原创 Size by Country
9.3.1 South America Parkinson's Disease Therapeutics Consumption Value by Country (2020-2031)
9.3.2 Brazil Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Parkinson's Disease Therapeutics Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Parkinson's Disease Therapeutics Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Parkinson's Disease Therapeutics 麻豆原创 Size by Country
10.3.1 Middle East & Africa Parkinson's Disease Therapeutics Consumption Value by Country (2020-2031)
10.3.2 Turkey Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Parkinson's Disease Therapeutics 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Parkinson's Disease Therapeutics 麻豆原创 Drivers
11.2 Parkinson's Disease Therapeutics 麻豆原创 Restraints
11.3 Parkinson's Disease Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Parkinson's Disease Therapeutics Industry Chain
12.2 Parkinson's Disease Therapeutics Upstream Analysis
12.3 Parkinson's Disease Therapeutics Midstream Analysis
12.4 Parkinson's Disease Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Merck
Akorn
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Roche
H.Lundbeck
Bausch Health
Apokyn
Orion
Stada Arzneimittel
US WorldMeds
Desitin Arzneimittel
Endo Pharmaceuticals
听
听
*If Applicable.
